Literature DB >> 17118603

Imaging of hepatic steatosis and fatty sparing.

Musturay Karcaaltincaba1, Okan Akhan.   

Abstract

Radiology has gained importance in the non-invasive diagnosis of hepatic steatosis. Ultrasonography is usually the first imaging modality for the evaluation of hepatic steatosis. Unenhanced CT with or without dual kVp measurement and MRI with in and out of phase sequence can allow objective evaluation of hepatic steatosis. However, none of the imaging modalities can differentiate non-alcoholic steatohepatitis/fatty liver disease from simple steatosis. Evaluation of hepatic steatosis is important in donor evaluation before orthotopic liver transplantation and hepatic surgery. Recently, one-stop shop evaluation of potential liver donors has become possible by CT and MRI integrating vascular, parenchymal, volume and steatosis evaluation. Moreover hepatic steatosis (diffuse, multinodular, focal, subcortical, perilesional, intralesional, periportal and perivenular), hypersteatosis and sparing (geographic, nodular and perilesional or peritumoral) can cause diagnostic problems as a pseudotumor particularly in the evaluation of oncology patients. Liver MRI is used as a problem-solving tool in these patients. In this review, we discuss the current role of radiology in diagnosing, quantifying hepatic steatosis and solutions for diagnostic problems associated with fatty infiltration and sparing.

Entities:  

Mesh:

Year:  2006        PMID: 17118603     DOI: 10.1016/j.ejrad.2006.11.005

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  26 in total

1.  Focal Fatty liver: more than just a radiographic curiosity?

Authors:  Heather M Patton; Joel E Lavine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

2.  Effect of pancreaticoduodenectomy on the course of hepatic steatosis.

Authors:  Hsin-Hsien Yu; Yan-Shen Shan; Pin-Wen Lin
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 3.  Non-alcoholic fatty liver disease: The diagnosis and management.

Authors:  Shehab M Abd El-Kader; Eman M Salah El-Den Ashmawy
Journal:  World J Hepatol       Date:  2015-04-28

4.  Frequency and implication of focal fatty sparing in segmental homogeneous fatty liver at ultrasound.

Authors:  Size Wu; Rong Tu; Guangqing Liu
Journal:  J Med Ultrason (2001)       Date:  2013-04-12       Impact factor: 1.314

5.  Comparison of new and conventional versions of model-based iterative reconstruction in reduced-dose computed tomography for diagnosis of hepatic steatosis.

Authors:  Koichiro Yasaka; Masaki Katsura; Jiro Sato; Masaaki Akahane; Izuru Matsuda; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2016-02-23       Impact factor: 2.374

6.  Development of poly(vinyl acetate-methylacrylic acid)/chitosan/Fe3O4 nanoparticles for the diagnosis of non-alcoholic steatohepatitis with magnetic resonance imaging.

Authors:  Xiadan Luo; Xiaoli Song; Aiping Zhu; Yunfeng Si; Lijun Ji; Zhanrong Ma; Zhiyun Jiao; Jingtao Wu
Journal:  J Mater Sci Mater Med       Date:  2012-09-14       Impact factor: 3.896

Review 7.  [Diffuse and vascular hepatic diseases].

Authors:  S Kreimeyer; L Grenacher
Journal:  Radiologe       Date:  2011-08       Impact factor: 0.635

Review 8.  Imaging patterns of fatty liver in pediatric patients.

Authors:  H Nursun Özcan; Berna Oğuz; Mithat Haliloğlu; Diclehan Orhan; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2015 Jul-Aug       Impact factor: 2.630

9.  A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses.

Authors:  Robert V Mulkern; Sandra Loeb Salsberg; Marta Ramon Krauel; David S Ludwig; Stephan Voss
Journal:  Pediatr Radiol       Date:  2008-08-02

Review 10.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.